Lillie, E. O., B. Patay, J. Diamant, B. Issell, E. J. Topol, and N. J. Schork. 2011. The N-of-1 clinical trial: The ultimate strategy for individualizing medicine? Personalized Medicine 8(2):161–173.

Mullard, A. 2012. FDA drug approvals. Nature Reviews Drug Discovery 11(2):91–94.

Munos, B. 2009. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8(12):959–968.

NRC (National Research Council). 2011. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press.

Patil, S. T., L. Zhang, F. Martenyi, S. L. Lowe, K. A. Jackson, B. V. Andreev, A. S. Avedisova, L. M. Bardenstein, I. Y. Gurovich, M. A. Morozova, S. N. Mosolov, N. G. Neznanov, A. M. Reznik, A. B. Smulevich, V. A. Tochilov, B. G. Johnson, J. A. Monn, and D. D. Schoepp. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nature Medicine 13(9):1102–1107.

Paul, S. M., D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, and A. L. Schacht. 2010. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery 9(3):203–214.

Pirmohamed, M., S. James, S. Meakin, C. Green, A. K. Scott, T. J. Walley, K. Farrar, B. K. Park, and A. M. Breckenridge. 2004. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. British Medical Journal 329(7456):15–19.

Pollack, A. 2010. Awaiting the genome payoff. New York Times, June 14, B1.

Ramsey, B. W., N. G. Davies, E. McElvaney, E. Tullis, S. C. Bell, P. Dimageevínek, M. Griese, E. F. McKone, C. E. Wainwright, M. W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S. M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordoñez, J. S. Elborn, and VX08-770-102 Study Group. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine 365(18):1663–1672.

Riess, J. W., and H. A. Wakelee. 2012. Metastatic non-small cell lung cancer management: Novel targets and recent clinical advances. Clinical Advances in Hematology & Oncology 10(4):226–234. http://www.clinicaladvances.com/article_pdfs/ho0412_reiss.pdf (accessed June 18, 2012).

Rikova, K., A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J. M. Ren, J. Yuan, C. E. Bakalarski, J. Villen, J. M. Kornhauser, B. Smith, D. Li, X. Zhou, S. P. Gygi, T. L. Gu, R. D. Polakiewicz, J. Rush, and M. J. Comb. 2007. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190–1203.

Scannell, J. W., A. Blanckley, H. Boldon, and B. Warrington. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery 11(3):191–200.

Sirota, M., J. T. Dudley, J. Kim, A. P. Chiang, A. A. Morgan, A. Sweet-Cordero, J. Sage, and A. T. Butte. 2011. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science Translational Medicine 3(96):96ra77.

Soda, M., Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, and H. Mano. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566.

Spear, B. B., M. Heath-Chiozzi, and J. Huff. 2001. Clinical application of pharmacogenetics. Trends in Molecular Medicine 7(5):201–204.

Trusheim, M. R., E. R. Berndt, and F. L. Douglas. 2007. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery 6(4):287–293.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement